On December 16, 2025, Annexon, Inc. in Brisbane, California, a biopharmaceutical company listed on Nasdaq as ANNX, revealed that it had awarded an equity grant to a new non-executive employee as part of the 2022 Employment Inducement Award Plan. The grant, approved on December 10, 2025, adhered to Nasdaq Listing Rule 5635(c)(4). Annexon focuses on developing a late-stage clinical platform that targets neuroinflammation in complement-mediated diseases affecting the body, brain, and eye.